REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ...
Private: Gallery Post #1
PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study! The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders ...
PDCI Market Access Inc. (PDCI), Canada’s leading pricing, reimbursement and health economics consultancy, is pleased to announce its strategic partnership with Mark Fleming. Mark is joining PDCI as Strategic Advisor supporting PDCI’s pricing, market access and policy research activities. ...
PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers
We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc. The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ...
Government Authorizes Temporary Compulsory Liscensing in Emergency Legislation for Products Needed to Respond to the COVID-19 Emergency
Bill C-13 is the government’s emergency legislation in response to the COVID-19 pandemic. The bill includes amendments to the Patent Act by adding a new section (19.4) which includes the following: Empowers the Minister of Health to require the Commissioner of Patents to authorize any person specified by the ...
The full list of submissions can be found here under the Submissions tab at the bottom of the page. Background: On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. The PMPRB ...
Good Afternoon, At PDCI Market Access Inc. (“PDCI”) we are committed to providing high quality services and deliverables to our clients. We also recognize the important responsibility we all have to prevent the spread of the COVID-19 outbreak. Based on the information received to date, we are currently implementing the following accommodations ...
PMPRB Cancellation of March 18th Policy Forum The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation. In order to provide stakeholders with an opportunity to convey information that may ...
Sharing Responses to the Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation
On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. Since then, the PMPRB has engaged with stakeholders to obtain feedback on its proposed pricing Guidelines. The consultation period closed on February 14, ...
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since ...